Development of High-Throughput ELISA Based Binding Assays to Detect p53/p63/p73 Family Protein-DNA Interaction in the 96-well Microplate Format for Drug Screening and Other Clinical and Diagnostic Uses
This technology includes ELISA based binding assays of p53, p63 or p73 provide possibilities to validate genome sequencing results, and allow the performance of more in-depth investigation to address scientific mechanisms, as well as to develop applications for high-throughput clinical and diagnosis usages. While quantitative p53 binding assays have been commercially developed, there is a lack of high-throughput method to detect binding activity of all three p53/p63/p73 family members, which are an important step for these transcription factors to perform their function.